Showing 6,561 - 6,580 results of 18,130 for search 'significantly ((((less decrease) OR (teer decrease))) OR (((we decrease) OR (a decrease))))', query time: 0.73s Refine Results
  1. 6561

    Data Sheet 1_Renewable energy consumption optimization allocation strategy for a regional microgrid based on a shared energy storage mechanism.zip by Hongde Ma (20137539)

    Published 2025
    “…This indicates that the proposed method for constructing a bilayer optimization configuration can effectively consider the economic consumption of new energy and significantly improve the economic operation of shared energy storage stations and regional microgrids.…”
  2. 6562

    Changes in the neutrophil count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  3. 6563

    Changes in the platelet count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  4. 6564

    Changes in the white blood cell count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  5. 6565

    Changes in the hemoglobin. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  6. 6566

    WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  7. 6567

    General clinical data of 88 patients with NPC. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  8. 6568

    CONSORT participant flow diagram. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  9. 6569

    S4 File - by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  10. 6570

    Renal function and risk of dementia: a Mendelian randomization study by Haowen Huang (1430386)

    Published 2024
    “…</p> <p>The findings indicate a significant correlation between each unit increase in cystatin C-based estimated glomerular filtration rate (eGFR-cys) levels was significantly associated with a reduction in the incidence of late-onset Alzheimer’s disease (LOAD) (IVW: OR = 0.35, 95% CI: 0.13–0.91, <i>p</i> = 0.031). …”
  11. 6571
  12. 6572
  13. 6573

    Table 1_A national framework for transition to precision medicine.docx by Samaneh Karimi Esboei (20623664)

    Published 2025
    “…The statistical sample of the study comprised PM specialists, researchers, and patients whose PM plays a significant role in their diagnosis and treatment. …”
  14. 6574

    Data Sheet 1_Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers.docx by Sergio Sánchez-García (16862127)

    Published 2025
    “…We found reduced levels in deceased patients when compared to mild or severe patients, concomitant with a decrease in the LXA<sub>4</sub> biosynthetic pathway and an increase in its degradation pathway. …”
  15. 6575

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  16. 6576

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  17. 6577

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  18. 6578

    Data Sheet 1_Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized control... by Sumaiah J. Alarfaj (12889115)

    Published 2025
    “…</p>Results<p>Compared to the placebo group (n = 24), the atorvastatin group (n = 23) exhibited a significant decrease in the level of IL-6 (p = 0.001), S1P (p = 0.0001), TNF-α (p = 0.003), NO (p = 0.0001), CRP (p = 0.015), ESR (p = 0.012), PMS (p = 0.013), and fecal calprotectin (p = 0.0003), and improved SF-36 (p = 0.006). …”
  19. 6579
  20. 6580